Hoffmann-La Roche Limited (Roche Canada)

At Roche Canada, patients and science are at the heart of everything we do. Our passion for science and our commitment to relentlessly pursuing the impossible for patients have made us one of the world’s leading pharmaceutical, in-vitro diagnostics, and diabetes care management companies.

With our combined strength in diagnostics and pharmaceuticals, we’re driving healthcare forward, while ensuring we deliver meaningful benefits for patients and sustainable healthcare systems. We are committed to creating a world where we all have more time with the people we love.

And we’re adding our expertise in new areas, such as artificial intelligence, real world data collection and analysis and collaborating with many different sectors and industries.

Having the courage to reinvent ourselves and question the status quo is what patients and healthcare systems expect from Roche - and our commitment is as strong today as it was on the first day of our Canadian journey in 1931. Today, Roche Canada employs nearly 2,000 people at its offices in Mississauga, Ontario, in Laval, Quebec, and across the country from coast to coast to coast.

For more information, please visit www.RocheCanada.com or follow Roche Canada on LinkedIn.



Contact Information
[email protected]
Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected.

Latest

Jun 11, 2025, 09:00 ET Health Canada Authorizes PiaSky® (crovalimab for injection) As the First Monthly (Every Four Weeks) Subcutaneous Treatment for People With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PiaSky® is the first monthly (every four weeks) subcutaneous treatment for PNH in Canada with the option to self-administer following adequate training(1) PiaSky® (crovalimab for injection) has the...

May 28, 2025, 09:00 ET New study led by Horizon and supported by Roche Canada delivers cancer treatment in the comfort of a patient's home

MISSISSAUGA, ON, May 28, 2025 /CNW/ - For the first time in Canada, a patient has received cancer immunotherapy by subcutaneous (under the skin) injection in their home, thanks to an innovative...

Feb 19, 2025, 09:00 ET Health Canada authorizes Itovebi® (inavolisib film-coated tablets), a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

The approval provides another treatment option for breast cancer patients with a PIK3CA mutation, one of the most commonly mutated genes in hormone receptor-positive disease, associated with poor...

Jan 20, 2025, 09:00 ET Health Canada Authorizes Vabysmo® (faricimab injection) Pre-Filled Syringe (PFS) for Three Leading Causes of Vision Loss

Vabysmo PFS is the first and only syringe prefilled with a Health-Canada approved bispecific antibody to treat retinal conditions that can cause blindness1 Designed to simplify administration,...

Dec 13, 2024, 09:00 ET Roche Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for TECENTRIQ SC (atezolizumab, solution for subcutaneous injection)

MISSISSAUGA, ON, Dec. 13, 2024 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) today announced that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for...

Nov 19, 2024, 09:15 ET Roche Canada Announces New Informatics Jobs in Ontario's Life Sciences Sector

These jobs will propel the province towards being a global leader in biomanufacturing and life sciences MISSISSAUGA, ON, Nov. 19, 2024 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to...

Oct 09, 2024, 08:00 ET Roche Canada Announces Columvi® (glofitamab for injection) is Publicly Reimbursed in 7 Provinces, Including Quebec, Ontario, Manitoba, Saskatchewan, Nova Scotia, and Newfoundland

Columvi is now publicly covered in 7 provinces, which equates to approximately 74% of the total Canadian population, and is the first and only fixed treatment duration bispecific antibody authorized...

Jul 29, 2024, 09:00 ET Health Canada Authorizes Vabysmo® (faricimab injection) for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion

This is the third indication for Vabysmo®, in addition to neovascular or 'wet' age-related macular degeneration and diabetic macular edema 1 Authorization is based on two phase III studies...

Jul 24, 2024, 08:00 ET Roche Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for COLUMVI® (glofitamab for injection) for the treatment of Diffuse Large B-cell Lymphoma

MISSISSAUGA, ON, July 24, 2024 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) today announced that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for...

Jul 16, 2024, 09:00 ET Health Canada authorizes Alecensaro® (alectinib) as the first and only adjuvant treatment for people with ALK-positive early-stage lung cancer

Alecensaro reduced the risk of disease recurrence or death by 76% in people with ALK-positive resected non-small cell lung cancer, as demonstrated in the Phase III ALINA study1 The approval addresses ...

Jun 06, 2024, 08:00 ET Innovative partnership aims to offer less invasive cancer treatment for New Brunswick patients

SAN DIEGO, June 6, 2024 /CNW/ - Horizon Health Network (Horizon), through an innovative partnership with Roche Canada, the New Brunswick Extra-Mural Program, the Government of New Brunswick and...

Apr 30, 2024, 09:00 ET CQDM, Roche, the Jewish General Hospital Foundation and McGill University fund research project of more than $9.4M on diabetic kidney disease

MONTREAL, April 30, 2024 /CNW/ - CQDM is proud to announce the funding of a collaborative research project to identify biomarkers and therapeutic solutions for diabetic kidney disease (DKD), one of...

Apr 23, 2024, 08:00 ET Health Canada authorizes Tecentriq® SC (atezolizumab, solution for subcutaneous injection), the first cancer immunotherapy subcutaneous injection, for multiple cancer types

Subcutaneous (SC) injection offers an alternative administration option to intravenous (IV) infusion, with the opportunity to provide greater flexibility and convenience for patients, healthcare...

Mar 12, 2024, 02:00 ET Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024

Roche introduces its suite of navify operational excellence solutions, including navify Analytics and navify Monitoring, for use in laboratories and point of care services navify Analytics provides...

Mar 07, 2024, 08:00 ET Columvi® (glofitamab for injection) receives positive CADTH and INESSS recommendations for adult patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL)

The process for Canadians to access new medicines is complex and involves several different federal, provincial, and territorial agencies. As Roche Canada, we stand ready to work collaboratively to...

Jan 11, 2024, 10:26 ET Roche Canada and McKesson Canada Inaugural Innovation Challenge Enhances the Patient Experience

Simple solutions yield impactful results - all projects selected by jury MISSISSAUGA, ON, Jan. 11, 2024 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is proud to announce a dynamic collaboration...

Dec 19, 2023, 01:00 ET Roche navify digital solutions get excellent ratings from healthcare professionals in KLAS Research reports

Roche announced today that healthcare professionals provided three of Roche's navify digital solutions with excellent ratings, in terms of performance and satisfaction, in an independent report by...

Sep 05, 2023, 01:00 ET Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare

The report shows digital health technologies demonstrate value, yet integrating them into care systems remains challenging. Involving healthcare professionals and patients in technology design and...

Aug 08, 2023, 01:00 ET New opportunities and persistent challenges revealed as organisations attempt more data-driven approaches to healthcare, says new report from Harvard Business Review Analytic Services

Ninety-four (94%) percent of global survey respondents working in healthcare agree that using data to drive healthcare creates new opportunities for patients and doctors to benefit from more...

May 29, 2023, 08:00 ET Roche Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for VABYSMO® (faricimab injection) for the treatment of Neovascular (Wet) Age-related Macular...

MISSISSAUGA, ON, May 29, 2023 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) today announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for ...

Apr 11, 2023, 01:00 ET Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions. navify...

Mar 25, 2023, 09:00 ET COLUMVI® (Glofitamab for Injection) Receives Health Canada Authorization with Conditions for Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

COLUMVI® (glofitamab for injection) is the first fixed treatment duration CD20xCD3 T-cell engaging bispecific antibody approved in Canada, and globally, to treat diffuse large B-cell lymphoma1, 2, 3...

Dec 01, 2022, 08:00 ET Roche Canada Announces Purchase Agreement with the Government of Canada for ACTEMRA® IV (tocilizumab for injection) for Treatment of Adult Patients with COVID-19

MISSISSAUGA, ON, Dec. 1, 2022 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) announced today that it has signed agreements with the Government of Canada to supply 15,000 treatment courses of...

Nov 24, 2022, 07:00 ET Health Canada Authorizes POLIVY® (polatuzumab vedotin for injection) for the First-Line Treatment of Adults With Large B-Cell Lymphoma

In Canada, it is estimated that in 2022, 11,400 Canadians will be diagnosed with non-Hodgkin lymphoma1, of which 30-40% of cases are diffuse large B-cell lymphoma subtype2 POLIVY® offers a new...

Nov 04, 2022, 02:00 ET Roche introduces the navify brand for its digital health solutions at HLTH 2022

Roche unifies its digital health portfolio under the navify brand, providing a range of next generation software solutions. The navify portfolio uses digital solutions, analytics and data science to...

Journalists and Bloggers

The news you need, when you need it.

Join PR Newswire for Journalists to access all of the free services designated to make your job easier.

In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.

LEARN MORE
Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected.